ALCMI Providing Samples for Validation of Exosome Dx's Lung Cancer Tests | GenomeWeb

NEW YORK(GenomeWeb) – Exosome Diagnostics today announced a collaboration with the Addario Lung Cancer Medical Institute in which the ALCMI is providing samples from an ongoing clinical trial to help Exosome advance its plasma-based lung cancer mutation tests.

According to Exosome, the collaboration will support the validation of its ALK and EGFR T790M liquid biopsy diagnostics, which the company plans to launch this year as laboratory-developed tests. The work will also support future development of these assays as IVD kits, Exosome added.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.